131 related articles for article (PubMed ID: 38154386)
1. Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma.
Kim GR; Kang JH; Kim HJ; Im E; Bae J; Kwon WS; Rha SY; Chung HC; Cho EY; Kim SY; Kim YC
Bioorg Chem; 2024 Feb; 143():107061. PubMed ID: 38154386
[TBL] [Abstract][Full Text] [Related]
2. Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
Kang JH; Lee JS; Hong D; Lee SH; Kim N; Lee WK; Sung TW; Gong YD; Kim SY
Cell Death Dis; 2016 Mar; 7(3):e2163. PubMed ID: 27031960
[TBL] [Abstract][Full Text] [Related]
3. Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models.
Ku BM; Kim SJ; Kim N; Hong D; Choi YB; Lee SH; Gong YD; Kim SY
J Cancer Res Clin Oncol; 2014 May; 140(5):757-67. PubMed ID: 24610445
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma.
Ku BM; Kim DS; Kim KH; Yoo BC; Kim SH; Gong YD; Kim SY
FASEB J; 2013 Sep; 27(9):3487-95. PubMed ID: 23704086
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma.
Kang JH; Lee SH; Lee JS; Oh SJ; Ha JS; Choi HJ; Kim SY
Cells; 2020 Jun; 9(6):. PubMed ID: 32560270
[TBL] [Abstract][Full Text] [Related]
6. Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition.
Lee SH; Lee WK; Kim N; Kang JH; Kim KH; Kim SG; Lee JS; Lee S; Lee J; Joo J; Kwon WS; Rha SY; Kim SY
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30463244
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma.
Lee SH; Kang JH; Ha JS; Lee JS; Oh SJ; Choi HJ; Song J; Kim SY
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708896
[TBL] [Abstract][Full Text] [Related]
8. Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma.
Bagatur Y; Ilter Akulke AZ; Bihorac A; Erdem M; Telci D
Cell Adh Migr; 2018 Mar; 12(2):138-151. PubMed ID: 28498731
[TBL] [Abstract][Full Text] [Related]
9. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
[TBL] [Abstract][Full Text] [Related]
10. Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus.
Kim N; Kang JH; Lee WK; Kim SG; Lee JS; Lee SH; Park JB; Kim KH; Gong YD; Hwang KY; Kim SY
Amino Acids; 2018 Nov; 50(11):1583-1594. PubMed ID: 30105541
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel target for renal cell carcinoma: transglutaminase 2.
Kang JH; Lee SH; Kim SY
Cell Death Dis; 2016 Apr; 7(4):e2200. PubMed ID: 27100894
[No Abstract] [Full Text] [Related]
12. A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2.
Kim SY; Keillor JW
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260198
[TBL] [Abstract][Full Text] [Related]
13. Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis.
Jang JH; Park JS; Lee TJ; Kwon TK
Cancer Lett; 2010 Jan; 287(2):224-30. PubMed ID: 19632032
[TBL] [Abstract][Full Text] [Related]
14. The p53 oncoprotein is a substrate for tissue transglutaminase kinase activity.
Mishra S; Murphy LJ
Biochem Biophys Res Commun; 2006 Jan; 339(2):726-30. PubMed ID: 16313886
[TBL] [Abstract][Full Text] [Related]
15. Combined Treatment with CCI779 and SB203580 Induces Cellular Senescence in Renal Cell Carcinoma Cell Line via p53 Pathway.
Chauhan A; Ojha R; Semwal DK; Mishra SP; Semwal RB
Anticancer Agents Med Chem; 2017 Nov; 17(11):1545-1554. PubMed ID: 28270077
[TBL] [Abstract][Full Text] [Related]
16. Transglutaminase 2 Inhibitor KCC009 Induces p53-Independent Radiosensitization in Lung Adenocarcinoma Cells.
Huaying S; Dong Y; Chihong Z; Xiaoqian Q; Danying W; Jianguo F
Med Sci Monit; 2016 Dec; 22():5041-5048. PubMed ID: 28002389
[TBL] [Abstract][Full Text] [Related]
17. Tissue transglutaminase-mediated chemoresistance in cancer cells.
Verma A; Mehta K
Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
[TBL] [Abstract][Full Text] [Related]
18. Sulforaphane covalently interacts with the transglutaminase 2 cancer maintenance protein to alter its structure and suppress its activity.
Rorke EA; Adhikary G; Szmacinski H; Lakowicz JR; Weber DJ; Godoy-Ruiz R; Puranik P; Keillor JW; Gates EWJ; Eckert RL
Mol Carcinog; 2022 Jan; 61(1):19-32. PubMed ID: 34610184
[TBL] [Abstract][Full Text] [Related]
19. Diosmetin Induces Apoptosis by Downregulating AKT Phosphorylation via P53 Activation in Human Renal Carcinoma ACHN Cells.
Qiu M; Liu J; Su Y; Guo R; Zhao B; Liu J
Protein Pept Lett; 2020; 27(10):1022-1028. PubMed ID: 32223728
[TBL] [Abstract][Full Text] [Related]
20. MiR-6838-5p facilitates the proliferation and invasion of renal cell carcinoma cells through inhibiting the DMTF1/ARF-p53 axis.
Zhai X; Wu Y; Zhang D; Li H; Chong T; Zhao J
J Bioenerg Biomembr; 2021 Apr; 53(2):191-202. PubMed ID: 33686550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]